Consensus Context Therapeutics Inc. Nasdaq

Equities

US21077P1084

Market Closed - Nasdaq Other stock markets 01:30:00 17/07/2024 am IST			5-day change	1st Jan Change
2.19 ^USD	-0.45%		+19.57%	+94.69%

08/05	Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
06/05	Context Therapeutics Inc. announced that it has received $99.992767 million in funding from Ally Bridge Group, Avidity Partners, LLC, Blue Owl Healthcare Opportunities, Deep Track Capital, LP, Driehaus Capital Management LLC, Great Point Partners, LLC	CI

Evolution of the average Target Price on Context Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

51bdb86cdaf7336826f1242fe54d7538.f9w3eVYtMtFsSHDCJn2rMS6VoXVq2PR8Ig8nNs7v70Q.NJhnI2dMSpMeODSJRTnIeB2hyQxYgo0qTVZMWoyIgj5Kig4fDnJQoR05Hw~b490eff8425c0a4a89b54060c81b3b02

Analysts' Consensus

Sell

Buy

Mean consensus

Number of Analysts

Last Close Price

Average target price

Consensus detail

Consensus revision (last 18 months)

EPS Revisions

Estimates Revisions